Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 15:409:116609.
doi: 10.1016/j.jns.2019.116609. Epub 2019 Dec 2.

Consensus recommendations on the management of multiple sclerosis patients in Argentina

Edgardo Cristiano  1 , Juan Ignacio Rojas  2 , Ricardo Alonso  3 , Amelia Alvez Pinheiro  4 , Elizabeth A Bacile  5 , María Eugenia Balbuena  6 , Andrés G Barboza  7 , Santiago Bestoso  8 , Marcos Burgos  9 , Fernando Cáceres  10 , Edgar Carnero Contentti  11 , María Celeste Curbelo  12 , Norma Deri  13 , Nora Fernandez Liguori  14 , María Ines Gaitán  15 , Orlando Garcea  16 , Diego Giunta  17 , Mario J Halfon  18 , Javier P Hryb  19 , Miguel Jacobo  20 , Eduardo Kohler  21 , Geraldine G Luetic  22 , Ignacio Maglio  23 , Alejandra D Martínez  24 , Jimena Míguez  2 , Pedro G Nofal  25 , Liliana Patrucco  2 , Raúl Piedrabuena  26 , Roberto Rotta Escalante  27 , María Laura Saladino  10 , Berenice A Silva  16 , Vladimiro Sinay  28 , Verónica Tkachuk  6 , Andrés Villa  29 , Carlos Vrech  30 , María Célica Ysrraelit  15 , Jorge Correale  15
Affiliations

Consensus recommendations on the management of multiple sclerosis patients in Argentina

Edgardo Cristiano et al. J Neurol Sci. .

Abstract

Introduction: During the last 20 years, multiple sclerosis (MS) disease has seen major changes with new diagnostic criteria, a better identification of disease phenotypes, individualization of disease prognosis and the appearance of new therapeutic options in relapsing remitting as well as progressive MS. As a result, the management of MS patients has become more complex and challenging. The objective of these consensus recommendations was to review how the disease should be managed in Argentina to improve long-term outcomes in MS patients.

Methods: A panel of 36 experts in neurology from Argentina, dedicated to the diagnosis and care of MS patients, gathered both virtually and in person during 2018 and 2019 to carry out a consensus recommendation on the management of MS patients in Argentina. To achieve consensus, the methodology of "formal consensus-RAND/UCLA method" was used.

Results: Recommendations focused on diagnosis, disease prognosis, tailored treatment, treatment failure identification and pharmacovigilance process.

Conclusions: The recommendations of these consensus guidelines attempt to optimize the health care and management of patients with MS in Argentina.

Keywords: Argentina; Consensus guideline; Diagnosis; MS care units; Multiple sclerosis; Personalized approach; Treatment management.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest RA, AAP, EAB, MEB, MB, EC, MCC, ND, MIG, OG, DG, MJH, JPH, MJ, EK, RL, JM, PGN, RP, MLS, VS, DS, AT, SAV, AV, CV has nothing to disclose. EC has received reimbursement for developing educational presentations, educational and research grants, consultation fees and travel stipends from Biogen, Genzyme, Merck, Novartis. AGB has received reimbursement for developing educational presentations, educational and research grants, consultation fees and travel stipends from Biogen, Genzyme, Novartis, Teva, Gador, Raffo, Biosidus, Synthon – Bagó and Roche. SB has received reimbursement for research grants and travel stipends from Merck, Biogen and Genzyme. FC received fees for consultancy and Advisory Board membership and fees for travel, academic conferences and research projects from Novartis, Merck-Serono, Teva, Genzyme and Biogen Idec. ECC has received reimbursement for developing educational presentations, educational and research grants, consultation fees and travel stipends from Biogen, Genzyme. NFL has received consulting fees from Biogen, Novartis and Genzyme as a lecturer from Merck Serono, Novartis and Biogen, and collaboration for attendance to national and international congresses from Biogen, Novartis, Merck Serono, Bayer and Gador. GGL has received reimbursement for developing educational presentations, consultations fees, clinical trials fees and travel stipends from Biogen, Genzyme, Merck, Novartis, Teva, Tuteur. ADM has received reimbursement for research grants, and travel stipends from Bagó, Raffo and Biosidus. LP has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Biogen, Genzyme, Merck, Novartis. JIR has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Biogen, Genzyme, Merck, Novartis. RRE has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Schering Argentina, Bayer Schering Pharma, Bayer, Serono Argentina and Merck. VS has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Bayer, Biogen, Genzyme, Merck, Novartis, Roche, Biosidus, Gador and Raffo. MCY has received reimbursement for developing educational presentations and travel/accommodations stipends from Merck-Serono Argentina, Biogen-Idec Argentina, Genzyme Argentina, Bayer Inc., Novartis Argentina and TEVA-Tuteur Argentina. JC has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Biogen, Genzyme, Merck, Novartis, and Roche.

MeSH terms